Outlook Therapeutics, Inc. (OTLK): Price and Financial Metrics
GET POWR RATINGS... FREE!
OTLK Stock Summary
- Revenue growth over the past 12 months for Outlook Therapeutics Inc comes in at -41.27%, a number that bests only 4.51% of the US stocks we're tracking.
- In terms of volatility of its share price, OTLK is more volatile than 98.66% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for OTLK comes in at -100.71% -- higher than that of just 4.01% of stocks in our set.
- Visit OTLK's SEC page to see the company's official filings. To visit the company's web site, go to www.oncobiologics.com.
OTLK Stock Price Chart Interactive Chart >
OTLK Price/Volume Stats
| Current price | $1.41 | 52-week high | $4.26 |
| Prev. close | $1.40 | 52-week low | $0.93 |
| Day low | $1.41 | Volume | 863 |
| Day high | $1.41 | Avg. volume | 1,352,986 |
| 50-day MA | $1.42 | Dividend yield | N/A |
| 200-day MA | $2.10 | Market Cap | 316.21M |
Outlook Therapeutics, Inc. (OTLK) Company Bio
Outlook Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company engages in identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics. Outlook Therapeutics focuses on monoclonal antibodies in the disease areas of immunology and oncology aspects. Outlook Therapeutics offers its services in the United States.
Latest OTLK News From Around the Web
Below are the latest news stories about Outlook Therapeutics Inc that investors may wish to consider to help them evaluate OTLK as an investment opportunity.
Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks ConferenceLive video webcast presentation on Tuesday, January 25th at 3:00 PM ETISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President & Chief Executive Officer will participate in the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 3:00 PM |
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022. |
Outlook Therapeutics to Present at the H.C. Wainwright BioConnect ConferenceISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022. A video webcast of the fire |
Outlook Therapeutics Updates 1 Key Risk FactorOutlook Therapeutics, Inc. (OTLK) is focused on developing 'bevacizumab,' an ophthalmic formulation for treating different retinal indications. Recently, Outlook reported positive data for LYTENAVA through multiple clinical trials for wet age-related macular degeneration (wet AMD). Outlook is expecting approval for its biologics license application (BLA) for LYTENAVA in the first quarter of the calendar year 2023. The company’s pre-launch commercial planning activities are in process for the anticipated approval. Outlook’s recent financing raise of $57.5 million is expected to provide support through this product launch. Upon approval, LYTENAVA can potentially address the multi-billion dollar U.S. market for wet AMD. |
Outlook Therapeutics (NASDAQ:OTLK) Earns Buy Rating from HC WainwrightHC Wainwright reiterated their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research note issued to investors on Thursday, TipRanks reports. They currently have a $6.00 price objective on the stock. Separately, Zacks Investment Research raised shares of Outlook Therapeutics from a sell rating to a hold rating in a research note on [] |
OTLK Price Returns
| 1-mo | -0.70% |
| 3-mo | -32.54% |
| 6-mo | -37.61% |
| 1-year | 3.68% |
| 3-year | -73.69% |
| 5-year | N/A |
| YTD | 3.68% |
| 2021 | 4.62% |
| 2020 | 120.34% |
| 2019 | -85.25% |
| 2018 | N/A |
| 2017 | N/A |
Continue Researching OTLK
Here are a few links from around the web to help you further your research on Outlook Therapeutics Inc's stock as an investment opportunity:Outlook Therapeutics Inc (OTLK) Stock Price | Nasdaq
Outlook Therapeutics Inc (OTLK) Stock Quote, History and News - Yahoo Finance
Outlook Therapeutics Inc (OTLK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...